MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/meg.0000000000002926

Медицинская библиотека · European journal of gastroenterology & hepatology · 2025

Efficacy and safety of tofacitinib for the treatment of moderate-to-severe ulcerative colitis in biologic-naive patients.

Liatsos Christos, Tzouvala Maria, Michalopoulos Georgios, Giouleme Olga, Karmiris Konstantinos, Kozompoli Dimitra, Mousourakis Konstantinos, Kyriakos Nikolaos, Giakoumis Marios, Striki Athanasia, Karoubalis Ioannis, Bellou Georgia, Zacharopoulou Eirini, Katsoula Anastasia, Kalogirou Maria, Viazis Nikos

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND AND AIMS: Tofacitinib has been approved for the treatment of patients with moderate-to-severe ulcerative colitis independently of prior therapies. We aimed to assess the efficacy and safety of tofacitinib in biologic-naive patients.

METHODS

This was a retrospective analysis of prospectively collected data extracted from the notes of patients with moderate-to-severe ulcerative colitis naive to advanced therapies, who were treated with tofacitinib [10 mg twice daily (b.i.d.) for 8 or 16 weeks followed by a 5 mg b.i.d. maintenance dose] in six Greek Hospitals, who had a follow-up of at least 26 weeks after treatment initiation.

RESULTS

Overall, 48 patients were included. Clinical response was seen in 30 (62.5%) and 32 (66.6%) patients at week 8 and 16, respectively. Clinical remission, corticosteroid-free clinical remission, biochemical response, and endoscopic remission at week 26 was observed in 26 (54.2%), 26 (54.2%), 28 (60.8%), and 29 (60.4%) patients, respectively. No major adverse events or infections were recorded.

CONCLUSION

In this retrospective ongoing cohort study, tofacitinib demonstrated clinical response at weeks 8 and 16 in more than 60% and steroid-free clinical remission at week 26 in more than 50% of biologic-naive patients with moderate-to-severe ulcerative colitis with a good safety profile, indicating that tofacitinib is an effective first-line treatment for this group of patients.

Для цитирования: Liatsos Christos, Tzouvala Maria, Michalopoulos Georgios, Giouleme Olga, Karmiris Konstantinos, Kozompoli Dimitra, Mousourakis Konstantinos, Kyriakos Nikolaos, Giakoumis Marios, Striki Athanasia, Karoubalis Ioannis, Bellou Georgia, Zacharopoulou Eirini, Katsoula Anastasia, Kalogirou Maria, Viazis Nikos. Efficacy and safety of tofacitinib for the treatment of moderate-to-severe ulcerative colitis in biologic-naive patients.. European journal of gastroenterology & hepatology. 2025. DOI: 10.1097/meg.0000000000002926.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.